Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX

Journal of Clinical Medicine

Volumn 6, Issue 4, 2017, Pages

  Rocino, Angiola ^a   Franchini, Massimo ^b   Coppola, Antonio ^c  

^a San Giovanni Bosco Hospital   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

^c FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

Bleeding; Bypassing therapy; Haemophilia; Inhibitors; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9 INHIBITOR; BLOOD CLOTTING INHIBITOR; UNCLASSIFIED DRUG;

HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX; PLATELET AGGREGATION ASSAY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 85034226942     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm6040046     Document Type: Review

References (95)

1. Gouw, S.C.; van den Berg, H.M.; Fischer, K.; Auerswald, G.; Carcao, M.; Chalmers, E.; Chambost, H.; Kurnik, K.; Liesner, R.; Petrini, P.; et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: The RODIN study. Blood 2013, 121, 4046–4055.
2. Hay, C.R.; Palmer, B.; Chalmers, E.; Liesner, R.; Maclean, R.; Rangarajan, S.; Williams, M.; Collins, P.W.; United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO). Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011, 117, 6367–6370.
3. Astermark, J. Inhibitor development: Patient-determined risk factors. Haemophilia 2010, 16, 66–70.
4. Gouw, S.C.; Fijnvandraat, K. Identifying non genetic risk factors for inhibitor development in severe hemophilia A. Semin. Thromb. Hemost. 2013, 39, 740–751.
5. Astermark, J.; Altisent, C.; Batorova, A.; Diniz, M.J.; Gringeri, A.; Holme, P.A.; Karafoulidou, A.; Lopez-Fernández, M.F.; Reipert, B.M.; Rocino, A.; et al. Non-genetic risk factors and the development of inhibitors in haemophilia: A comprehensive review and consensus report. Haemophilia 2010, 16, 747–766.
6. D’Oiron, R.; Pipe, S.W.; Jacquemin, M. Mild/moderate haemophilia A: New insights into molecular mechanisms and inhibitor development. Haemophilia 2008, 14, 138–146.
7. Mauser-Bunschoten, E.P.; Den Ujil, I.E.; Schutgens, R.E.; Roosendaal, G.; Fischer, K. Risk of inhibitor development in mild haemophilia A increases with age. Haemophilia 2012, 18, 263–267.
8. Eckhardt, C.L.; van Velzen, A.S.; Peters, M.; Astermark, J.; Brons, P.P.; Castaman, G.; Cnossen, M.H.; Dors, N.; Escuriola-Ettingshausen, C.; Hamulyak, K.; et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013, 122, 1954–1962.
9. Eckhardt, C.L.; Menke, L.A.; Van Ommen, C.H.; van der Lee, J.H.; Geskus, R.B.; Kamphuisen, P.W.; Peters, M.; Fijnvandraat, K. Intensive perioperative use of factor VIII and the Arg593–>Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J. Thromb. Haemost. 2009, 7, 930–937.
10. DiMichele, D. Inhibitor development in haemophilia B: An orphan disease in need of attention. Br. J. Haematol. 2007, 138, 305–315.
11. Goodeve, A.C. Hemophilia B: Molecular pathogenesis and mutation analysis. J. Thromb. Haemost. 2015, 13, 1184–1195.
12. White, G.C., II; Rosendaal, F.; Aledort, L.M.; Lusher, J.M.; Rothschild, C.; Ingerslev, J.; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the international society of thrombosis and haemostasis. Thromb. Haemost. 2001, 85, 560.
13. Gringeri, A.; Mantovani, L.G.; Scalone, L.; Mannucci, P.M.; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: The COCIS Study Group. Blood 2003, 102, 2358–2363.
14. Morfini, M.; Haya, S.; Tagariello, G.; Pollmann, H.; Quintana, M.; Siegmund, B.; Stieltjes, N.; Dolan, G.; Tusell, J. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007, 13, 606–612.
15. Scalone, L.; Mantovani, L.G.; Mannucci, P.M.; Gringeri, A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006, 12, 154–162.
16. Srivastava, A.; Brewer, A.K.; Mauser-Bunschoten, E.P.; Key, N.S.; Kitchen, S.; Llinas, A.; Ludlam, C.A.; Mahlangu, J.N.; Mulder, K.; Poon, M.C.; et al. Guidelines for the management of hemophilia. Haemophilia 2013, 19, e1–e47.
17. Collins, P.W.; Chalmers, E.; Hart, D.P.; Liesner, R.; Rangarajan, S.; Talks, K.; Williams, M.; Hay, C.R. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). Br. J. Haematol. 2013, 160, 153–170.
18. Rocino, A.; Coppola, A.; Franchini, M.; Castaman, G.; Santoro, C.; Zanon, E.; Santagostino, E.; Morfini, M.; Italian Association of Haemophilia Centres (AICE) Working Party. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus. 2014, 12, 575–598.
19. Brackmann, H.H.; Lenk, H.; Scharrer, I.; Auerswald, G.; Kreuz, W. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999, 5, 203–206.
20. Valentino, L.A.; Kempton, C.L.; Kruse-Jarres, R.; Mathew, P.; Meeks, S.L.; Reiss, U.M.; International Immune Tolerance Induction Study Investigators. US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitors. Haemophilia 2015, 21, 559–567.
21. Colvin, B.T.; Astermark, J.; Fischer, K.; Gringeri, A.; Lassila, R.; Schramm, W.; Thomas, A.; Ingerslev, J.; Inter DisciplinaryWorking Group. European principles of haemophilia care. Haemophilia 2008, 14, 361–374.
22. Astermark, J.; Morado, M.; Rocino, A.; van den Berg, H.M.; von Depka, M.; Gringeri, A.; Mantovani, L.; Garrido, R.P.; Schiavoni, M.; Villar, A.; et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006, 12, 363–371.
23. DiMichele, D.M.; Hoots, W.K.; Pipe, S.W.; Rivard, G.E.; Santagostino, E. International workshop on immune tolerance induction: Consensus recommendations. Haemophilia 2007, 13, 1–22.
24. Benson, G.; Auerswald, G.; Elezovic, I.; Lambert, T.; Ljung, R.; Morfini, M.; Remor, E.; Salek, S.Z. Immune tolerance induction in patients with severe hemophilia with inhibitors: Expert panel views and recommendations for clinical practice. Eur. J. Haematol. 2012, 88, 371–379.
25. Colowick, A.B.; Bohn, R.L.; Avorn, J.; Ewenstein, B.M. Immune tolerance induction in hemophilia patients with inhibitors: Costly can be cheaper. Blood 2000, 96, 1698–1702.
26. Rocino, A.; Cortesi, P.A.; Scalone, L.; Mantovani, L.G.; Crea, R.; Gringeri, A.; European Haemophilia Therapy Strategy Board (EHTSB). Immune tolerance induction in patients with haemophilia a and inhibitors: Effectiveness and cost analysis in an European Cohort (The ITER Study). Haemophilia 2016, 22, 96–102.
27. Earnshaw, S.R.; Graham, C.N.; McDade, C.L.; Spears, J.B.; Kessler, C.M. Factor VIII alloantibody inhibitors: Cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia 2015, 21, 310–319.
28. DiMichele, D. The North American Immune Tolerance Registry: Contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 2009, 15, 320–328.
29. Chitlur, M.; Warrier, I.; Rajpurkar, M.; Lusher, J.M. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997–2006). Haemophilia 2009, 15, 1027–1031.
30. Holstein, K.; Batorova, A.; Carvalho, M.; Fijnvandraat, K.; Holme, P.; Kavakli, K.; Lambert, T.; Rocino, A.; Jiménez-Yuste, V.; Astermark, J.; et al. Current view and outcome of ITI therapy—A change over time? Thromb. Res. 2016, 148, 38–44.
31. Castaman, G.; Bonetti, E.; Messina, M.; Morfini, M.; Rocino, A.; Scaraggi, F.A.; Tagariello, G.; Italian Association of Hemophilia Centers. Inhibitors in haemophilia B: The Italian experience. Haemophilia 2013, 19, 686–690.
32. Castaman, G.; Fijnvandraat, K. Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mildhemophilia A. Blood 2014, 124, 2333–2336.
33. Kempton, C.L.; Allen, G.; Hord, J.; Kruse-Jarres, R.; Pruthi, R.K.; Walsh, C.; Young, G.; Soucie, J.M. Eradication of factor VIII inhibitors in patients with mild and moderate haemophilia A. Am. J. Hematol. 2012, 87, 933–936.
34. Van Veltzen, A.S.; Eckhardt, C.L.; Hart, D.P.; Peters, M.; Rangarajan, S.; Mancuso, M.E.; Smiers, F.J.; Khair, K.; Petrini, P.; Jiménez-Yuste, V.; et al. Inhibitors in nonsevere haemophilia A: Outcome and eradication strategies. Thromb. Haemost. 2015, 114, 46–55.
35. Gringeri, A.; Mannucci, P.M.; Italian Association of Haemophilia Centres. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005, 11, 611–619.
36. Kempton, C.L.; White, G.C., 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009, 113, 11–17.
37. Lillicrap, D.; Schiviz, A.; Apostol, C.; Wojciechowski, P.; Horling, F.; Lai, C.K.; Piskernik, C.; Hoellriegl, W.; Lollar, P. Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): Product characteristics and preclinical profile. Haemophilia 2016, 22, 308–317.
38. Roberts, H.R.; Monroe, D.M.; White, G.C. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004, 104, 3858–3864.
39. Hoffman, M.; Dargaud, Y. Mechanisms and monitoring of bypassing agent therapy. J. Thromb. Haemost. 2012, 10, 1478–1485.
40. Villar, A.; Aronis, S.; Morfini, M.; Santagostino, E.; Auerswald, G.; Thomsen, H.F.; Erhardtsen, E.; Giangrande, P.L. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004, 10, 352–359.
41. Turecek, P.L.; Váradi, K.; Gritsch, H.; Schwarz, H.P. FEIBA: Mode of action. Haemophilia 2004, 10, 3–9.
42. Franchini, M.; Coppola, A.; Tagliaferri, A.; Lippi, G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin. Thromb. Hemost. 2013, 39, 772–778.
43. Iorio, A.; Matino, D.; D’Amico, R.; Makris, M. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst. Rev. 2010, 8, CD004449.
44. Negrier, C.; Gomperts, E.D.; Oldenburg, J. The history of FEIBA: A lifetime of success in the treatment of hemophilia complicated by an inhibitor. Haemophilia 2006, 12, 4–13.
45. Key, N.S.; Aledort, L.M.; Beardsley, D.; Cooper, H.A.; Davignon, G.; Ewenstein, B.M.; Gilchrist, G.S.; Gill, J.C.; Glader, B.; Hoots, W.K.; et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb. Haemost. 1998, 80, 912–918.
46. Santagostino, E.; Gringeri, A.; Mannucci, P.M. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early intervention. Br. J. Haematol. 1999, 104, 22–26.
47. Kavakli, K.; Makris, M.; Zulfikar, B.; Erhardtsen, E.; Abrams, Z.S.; Kenet, G.; NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, crossover trial. Thromb. Haemost. 2006, 95, 600–605.
48. Santagostino, E.; Mancuso, M.E.; Rocino, A.; Mancuso, G.; Scaraggi, F.; Mannucci, P.M. A prospective randomised trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J. Thromb. Haemost. 2006, 4, 367–371.
49. Astermark, J.; Donfield, S.M.; DiMichele, D.M.; Gringeri, A.; Gilbert, S.A.; Waters, J.; Berntorp, E.; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007, 109, 546–551.
50. Young, G.; Shafer, F.E.; Rojas, P.; Seremetis, S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: A randomized comparison. Haemophilia 2008, 14, 287–294.
51. Negrier, C.; Goudemand, J.; Sultan, Y.; Bertrand, M.; Rothchild, C.; Lauroua, P.; the French FEIBA Study Group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb. Haemost. 1997, 77, 1113–1119.
52. Escuriola-Ettingshausen, C.; Kreuz, W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series. Haemophilia 2010, 16, 90–100.
53. Teitel, J.; Berntorp, E.; Collins, P.; D’Oiron, R.; Ewenstein, B.; Gomperts, E.; Goudemand, J.; Gringeri, A.; Key, N.; Leissinger, C.; et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007, 13, 256–263.
54. Key, N.S.; Christie, B.; Henderson, N.; Nelsestuen, G.L. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb. Haemost. 2002, 88, 60–65.
55. Tomokiyo, K.; Nakatomi, Y.; Araki, T.; Teshima, K.; Nakano, H.; Nakagaki, T.; Miyamoto, S.; Funatsu, A.; Iwanaga, S. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: Evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone. Vox Sang. 2003, 85, 290–299.
56. Schneiderman, J.; Rubin, E.; Nugent, D.J.; Young, G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: Update of our previous experience. Haemophilia 2007, 13, 244–248.
57. Gringeri., A.; Fischer, K.; Karafoulidou, A.; Klamroth, R.; Lopez-Fernandez, M.F.; Mancuso, E. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia 2011, 17, 630–635.
58. Astermark, J.; Rocino, A.; Von Depka, M.; Van Den Berg, H.M.; Gringeri, A.; Mantovani, L.G.; Morado, M.; Garrido, R.P.; Schiavoni, M.; Villar, A.; et al. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 2007, 13, 38–45.
59. Hay, C.R.; Ludlam, C.A.; Colvin, B.T.; Hill, F.G.; Preston, F.E.; Wasseem, N.; Bagnall, R.; Peake, I.R.; Berntorp, E.; Mauser Bunschoten, E.P.; et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Thromb. Haemost. 1998, 79, 762–766.
60. Ehrlich, H.J.; Henzl, M.J.; Gomperts, E.D. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-Year compilation of thrombotic adverse events. Haemophilia 2002, 8, 83–90.
61. Dimichele, D.; Négrier, C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006, 12, 352–362.
62. Negrier, C.; Voisin, S.; Baghaei, F.; Numerof, R.; Novack, A.; Doralt, J.E.; Romanov, V.; Gringeri, A.; FEIBA PASS Study Group. Global Post-Authorization Safety Surveillance Study: Real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate). Blood. Coagul. Fibrinolysis 2016, 27, 551–556.
63. Roberts, H.R.; Monroe, D.M., 3rd; Hoffman, M. Safety profile of recombinant factor VIIa. Semin. Hematol. 2004, 41, 101–108.
64. Aledort, L.M. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus FVIII bypassing activity. J. Thromb. Haemost. 2004, 2, 1700–1708.
65. Tran, H.T.; Sørensen, B.; Rea, C.J. Bypassing agent therapy with and without tranexamic acid in haemophilia a patients with inhibitors—An in vivo prospective crossover study. Lancet 2013, 1, 1–10.
66. Valentino, L.A.; Holme, P.A. Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly? Haemophilia 2015, 21, 709–714.
67. Makris, M.; Hay, C.R.; Gringeri, A.; D’Oiron, R. How I treat inhibitors in haemophilia. Haemophilia 2012, 18, 48–53.
68. Váradi, K.; Negrier, C.; Berntorp, E.; Astermark, J.; Bordet, J.C.; Morfini, M.; Linari, S.; Schwarz, H.P.; Turecek, P.L. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J. Thromb. Haemost. 2003, 1, 2374–2380.
69. Sørensen, B.; Ingerslev, J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J. Thromb. Haemost. 2004, 2, 102–110.
70. Chitlur, M. Challenges in the laboratory analyses of bleeding disorders. Thromb. Res. 2012, 130, 1–6.
71. Mancuso, M.E.; Fasulo, M.R. Thrombin generation assay as a laboratory monitoring tool during bypassing therapy in patients with hemophilia and inhibitors. Semin. Thromb. Hemost. 2016, 42, 30–35.
72. Berntorp, E.; Collins, P.; D’Oiron, R.; Ewing, N.; Gringeri, A.; Négrier, C.; Young, G. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: A consensus definition. Haemophilia. 2011, 17, e202–e210.
73. Gringeri, A.; Lambert, T.; Street, A.; Aledort, L.; Adolescent/Adult Prophylaxis ExpertWorking Group of the International Prophylaxis Study Group. Tertiary prophylaxis in adults: Is there a rationale? Haemophilia 2012, 18, 722–728.
74. Valentino, L.A. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia 2010, 16, 263–271.
75. Young, G.; Auerswald, G.; Jimenez-Yuste, V.; Lambert, T.; Morfini, M.; Santagostino, E.; Blanchette, V. PRO-PACT: Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb. Res. 2012, 130, 864–870.
76. Konkle, B.A.; Ebbesen, L.S.; Erhardtsen, E.; Bianco, R.P.; Lissitchkov, T.; Rusen, L.; Serban, M.A. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J. Thromb. Haemost. 2007, 5, 1904–1913.
77. Leissinger, C.; Gringeri, A.; Antmen, B.; Berntorp, E.; Biasoli, C.; Carpenter, S.; Cortesi, P.; Jo, H.; Kavakli, K.; Lassila, R.; et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N. Engl. J. Med. 2011, 365, 1684–1692.
78. Antunes, S.V.; Tangada, S.; Stasyshyn, O.; Mamonov, V.; Phillips, J.; Guzman-Becerra, N.; Grigorian, A.; Ewenstein, B.; Wong, W.Y. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014, 20, 65–72.
79. Hoots, W.K.; Ebbesen, L.S.; Konkle, B.A.; Auerswald, G.K.; Roberts, H.R.; Weatherall, J.; Ferran, J.M.; Ljung, R.C.; Novoseven (F7HAEM-1505) Investigators. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008, 14, 466–475.
80. Gringeri, A.; Leissinger, C.; Cortesi, P.A.; Jo, H.; Fusco, F.; Riva, S.; Antmen, B.; Berntorp, E.; Biasoli, C.; Carpenter, S.; et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: Results from the Pro-FEIBA study. Haemophilia 2013, 19, 736–743.
81. Young, G.; Auerswald, G.; Jimenez-Yuste, V.; Konkle, B.A.; Lambert, T.; Morfini, M.; Santagostino, E.; Blanchette, V. When should prophylaxis therapy in inhibitor patients be considered? Haemophilia 2011, 17, e849–e857.
82. López-Fernández, M.F.; Altisent Roca, C.; Álvarez-Román, M.T.; Canaro Hirnyk, M.I.; Mingot-Castellano, M.E.; Jiménez-Yuste, V.; Cid Haro, A.R.; Pérez-Garrido, R.; Sedano Balbas, C. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. Thromb. Haemost. 2016, 115, 872–895.
83. Brackmann, H.H.; Oldenburg, J.; Schwaab, R. Immune tolerance for the treatment of factor VIII inhibitors—Twenty years of the Bonn Protocol. Vox Sang. 1996, 70, 30–35.
84. Jiménez-Yuste, V.; Alvarez, M.T.; Martin-Salces, M.; Quintana, M.; Rodriguez-Merchan, C.; Lopez-Cabarcos, C.; Velasco, F.; Hernández-Navarro, F. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: Different approaches for different clinical situations. Haemophilia 2009, 15, 203–209.
85. Manco-Johnson, M.J.; Abshire, T.C.; Shapiro, A.D.; Riske, B.; Hacker, M.R.; Kilcoyne, R.; Ingram, J.D.; Manco-Johnson, M.L.; Funk, S.; Jacobson, L.; et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N. Engl. J. Med. 2007, 357, 535–544.
86. Olivieri, M.; Kurnik, K.; Pfluger, T.; Bidlingmaier, C. Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis. Haemophilia 2012, 18, 369–374.
87. Kraft, J.; Blanchette, V.; Babyn, P.; Feldman, B.; Cloutier, S.; Israels, S.; Pai, M.; Rivard, G.E.; Gomer, S.; McLimont, M.; et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J. Thromb. Haemost. 2012, 10, 2494–2502.
88. Roosendaal, G.; Vianen, M.E.; Marx, J.J.; van den Berg, H.M.; Lafeber, F.P.; Bijlsma, J.W. Blood-induced joint damage: A human in vitro study. Arthritis Rheum. 1999, 42, 1025–1032.
89. Jansen, N.W.; Roosendaal, G.; Bijlsma, JW.; Degroot, J.; Lafeber, F.P. Exposure of human cartilage tissue to low concentrations of blood for a short period of time leads to prolonged cartilage damage: An in vitro study. Arthritis Rheum. 2007, 56, 199–207.
90. Di Minno, M.N.; Ambrosino, P.; Quintavalle, G.; Coppola, A.; Tagliaferri, A.; Martinoli, C.; Rivolta, G.F. Assessment of hemophilic arthropathy by ultrasound: Where do we stand? Semin. Thromb. Hemost. 2016, 42, 541–549.
91. Gringeri, A.; Ewenstein, B.; Reininger, A. The burden of bleeding in haemophilia: Is one bleed too many? Haemophilia 2014, 20, 459–463.
92. Valentino, L.A.; Hakobyan, N.; Enockson, C.; Simpson, M.L.; Kakodkar, N.C.; Cong, L.; Song, X. Exploring the biological basis of haemophilic joint disease: Experimental studies. Haemophilia 2012, 18, 310–318.
93. Fischer, K. Prophylaxis for adults with haemophilia: One size does not fit all. Blood Transfus. 2012, 10, 169–173.
94. Di Minno, M.N.; Di Minno, G.; Di Capua, M.; Cerbone, A.M.; Coppola, A. Cost of care of haemophilia with inhibitors. Haemophilia 2010, 16, e190–e201.
95. Hay, J.W.; Zhou, Z.Y. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors. Haemophilia 2011, 17, e969–e974.